脂蛋白(a)与动脉粥样硬化性心血管疾病和主动脉瓣狭窄

发布:2026年7月22日更新:2026年7月22日

Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L等

European Heart Journal · 2022; 43(39):3925-3946

本综述评估None (consensus guidance on once-in-a-lifetime Lp(a) testing, risk assessment, and management of elevated levels via lifestyle and control of other risk factors; no specific Lp(a)-lowering drug tested)与Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment的关系。证据等级：Ia。

摘要速览

循证研究：脂蛋白(a)与动脉粥样硬化性心血管疾病

医学审核:WellAlly 编辑团队最后审核 2026年7月22日编辑政策

关键信息一览

DOI: 10.1093/eurheartj/ehac361
PMID: 36036785
PMC: PMC9639807
期刊: European Heart Journal
年份: 2022
卷: 43
期: 39
页码: 3925-3946
研究类型: 指南
证据等级: Ia
干预措施: None (consensus guidance on once-in-a-lifetime Lp(a) testing, risk assessment, and management of elevated levels via lifestyle and control of other risk factors; no specific Lp(a)-lowering drug tested)
主要终点: Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment
随访时长: Not applicable (evidence review of studies with varying durations)
资金来源: foundation
开放获取: 是

研究概述

本研究探讨了None (consensus guidance on once-in-a-lifetime Lp(a) testing, risk assessment, and management of elevated levels via lifestyle and control of other risk factors; no specific Lp(a)-lowering drug tested)对Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment的影响。

关键发现

研究结果为Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment提供了重要证据。

临床结论

详见原始文献。证据等级：Ia。

Abstract

"本临床指南综述了None (consensus guidance on once-in-a-lifetime Lp(a) testing, risk assessment, and management of elevated levels via lifestyle and control of other risk factors; no specific Lp(a)-lowering drug tested)与Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment的研究证据。

Funding & conflicts of interest

资金来源: foundation

COI: Multiple authors reported research grants, consulting fees, or honoraria from pharmaceutical companies developing lipid therapies

本信息仅供教育用途，不能替代专业医疗建议、诊断或治疗。

医学免责声明

本内容仅供一般信息和教育用途，不能替代专业医疗建议、诊断或治疗。对于任何医疗问题，请务必咨询合格的医疗服务提供者；切勿因阅读本站内容而忽视专业医疗建议或推迟就医。

如果您认为自己可能出现医疗紧急情况，请立即拨打当地急救电话或前往最近的急诊科。

医学审核:WellAlly 编辑团队最后审核 2026年7月22日. · 阅读我们的编辑政策